





# Mediterranean Journal of Rheumatology

## October 2020 Progress Report

Fact: The Mediterranean Journal of Rheumatology is undergoing the best period of its 30 year history



Fact: The Mediterranean Journal of Rheumatology is undergoing the best period of its 30 year history



Fact: The Mediterranean Journal of Rheumatology is undergoing the best period of its 30 year history


Initial Goal:

To reach 60 papers in 2020 and establish  
a three-figure yearly average by 2021

Current Status:

Three-figure yearly average has been reached by September 2020  
(Current total submissions in October 2020: 141)

Fact: The Mediterranean Journal of Rheumatology is undergoing the best period of its 30 year history



We aim to reach 30,000 visits by the end of 2020

# Indexes – Partnerships – Aggregators

- **Scopus**
- **PubMed Central**
- BASE - Bielefeld Academic Search Engine
  - CNKI
  - CrossRef Partner
  - Cyberleninka
    - DOAJ
  - Google Scholar
- J-Gate Aggregator
  - Open Archives
    - Portico
    - ProQuest
  - SFDora.org
  - Ulrichsweb
    - VINITI

## Successes in Indexing



Dec 2019:

Accepted in PubMed



Oct 2020:

Accepted in Scopus





# Special Issues



Jun 2020:  
JAK Inhibitors



Sep 2020:  
COVID-19

More to come...



Ongoing: Diet and  
Rheumatic Diseases





# Social Media



**MJR**  
@MJR\_journal

MJR is an international, peer-reviewed platinum open access journal aims to publish innovative evidence-based articles in all fields of the rheumatic diseases.

📍 Greece 🔗 [mjrheum.org/home](https://mjrheum.org/home) 📅 Joined April 2018

856 Following 485 Followers

[Edit profile](#)



MJR @MJR\_journal · Oct 13

Management of patients with inflammatory diseases during the #COVID19 pandemic.

📌 The purpose of this position statement is to provide up-to-date guidance for better management of patients with #InflammatoryDiseases during the COVID19 pandemic.

👉 [bit.ly/3dnUkLz](https://bit.ly/3dnUkLz)

## The key points of the position statement

- Patients with inflammatory diseases who receive moderate or high-risk anti-inflammatory therapies might be considered as an increased risk group for severe COVID-19 and appropriate measures should be taken in order to protect them.
- Initiation of immuno-suppressive/modulatory therapies should be done with caution, taking into account the severity of the underlying inflammatory disease, the type of anti-inflammatory treatment, and the risk of exposure to the SARS-CoV-2 virus.
- Discontinuation of anti-inflammatory therapies in patients who have not been exposed to or infected with the SARS-CoV-2 virus is not recommended.
- In patients who become infected with SARS-CoV-2, anti-inflammatory therapies should be discontinued, except in special cases.
- Specialty physicians should actively participate in the Interdisciplinary Teams caring for patients with inflammatory diseases during COVID19 infection.



11



20





# Endorsements



## 2020 Goals

Scientific & Financial Cash-In of our achievements ?

Reach out to the international market ?

Publication of proceedings of international conferences

First video publication

Application for inclusion in Scopus ?

Application for inclusion in MedLine ?

Establish a firm rejection rate ?

**Thank you for your attention!**

